EUVIMEDEUVIMED entdecken
Open Access

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection

Mimi M Hou iD, Jordan R Barrett iD, Yrene Themistocleous iD, Thomas A Rawlinson, Ababacar Diouf, Francisco J Martinez iD, Carolyn M Nielsen iD, Amelia M Lias iD, Lloyd D W King, Nick J Edwards iD, Nicola M Greenwood, Lucy Kingham und 24 weitere

Science Translational Medicine · 12.07.2023 · 15 (704)

DOI: 10.1126/scitranslmed.adf1782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 12.07.2023. Verfasst von Mimi M Hou und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK. Hauptthemen laut MEDLINE: Malaria, Parasites. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Department of Health, Wellcome Trust, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are no licensed vaccines against Plasmodium vivax . We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% ( n = 6) compared with unvaccinated controls ( n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MalariaParasitesVaccinationPlasmodium vivaxHumansAnimalsVaccinia virus

Autor:innen und Institutionen

  • Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
  • Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
  • Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
  • Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.
  • Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.

ORCID-Profile: Mimi M Hou, Jordan R Barrett, Yrene Themistocleous, Francisco J Martinez, Carolyn M Nielsen, Amelia M Lias, Nick J Edwards, Ian D Poulton, Baktash Khozoee, Cyndi Goh, Susanne H Hodgson, Dylan J Mac Lochlainn, Jo Salkeld, Christèle Huon, Jenny M Reimer, Paushali Mukherjee, Iona J Taylor, Fay L Nugent, Carole A Long, Robert W Moon, Kazutoyo Miura, Sarah E Silk, Chetan E Chitnis, Angela M Minassian, Simon J Draper

Förderung

  • Department of Health
  • Wellcome Trust
  • Medical Research Council

Zitieren

APA

Hou, M. M., Barrett, J. R., Themistocleous, Y., Rawlinson, T. A., Diouf, A., Martinez, F. J., Nielsen, C. M., Lias, A. M., King, L. D. W., Edwards, N. J., Greenwood, N. M., Kingham, L., Poulton, I. D., Khozoee, B., Goh, C., Hodgson, S. H., Mac Lochlainn, D. J., Salkeld, J., Guillotte-Blisnick, M., …, & Draper, S. J. (2023). Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection. Science Translational Medicine, 15(704). https://doi.org/10.1126/scitranslmed.adf1782

Vancouver

Hou MM, Barrett JR, Themistocleous Y, Rawlinson TA, Diouf A, Martinez FJ, et al. Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection. Science Translational Medicine. 2023;15(704). doi:10.1126/scitranslmed.adf1782

BibTeX
@article{Hou2023,
  author = {Hou, Mimi M and Barrett, Jordan R and Themistocleous, Yrene and Rawlinson, Thomas A and Diouf, Ababacar and Martinez, Francisco J and Nielsen, Carolyn M and Lias, Amelia M and King, Lloyd D W and Edwards, Nick J and Greenwood, Nicola M and Kingham, Lucy and Poulton, Ian D and Khozoee, Baktash and Goh, Cyndi and Hodgson, Susanne H and Mac Lochlainn, Dylan J and Salkeld, Jo and Guillotte-Blisnick, Micheline and Huon, Christèle and Mohring, Franziska and Reimer, Jenny M and Chauhan, Virander S and Mukherjee, Paushali and Biswas, Sumi and Taylor, Iona J and Lawrie, Alison M and Cho, Jee-Sun and Nugent, Fay L and Long, Carole A and Moon, Robert W and Miura, Kazutoyo and Silk, Sarah E and Chitnis, Chetan E and Minassian, Angela M and Draper, Simon J},
  title = {Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection},
  journal = {Science Translational Medicine},
  year = {2023},
  volume = {15},
  number = {704},
  doi = {10.1126/scitranslmed.adf1782}
}
Kostenlos starten →